Sylvain Choquet

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 726 citations · Full text

Medicine, Hematology, Oncology +12

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Ajai Chari, Dan T. Vogl, Maria Gavriatopoulou et al. · New England Journal of Medicine · 2019 · 673 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study

Sylvain Choquet · Blood · 2005 · 425 citations · Full text

Life Sciences, Hematology, Immunology +12

Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial

Ralf Ulrich Trappe, Stephan Oertel, Véronique Leblond et al. · The Lancet Oncology · 2011 · 386 citations

Medicine, Immunology, Oncology +9

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma

Emmanuel Bachy, Steven Le Gouill, Roberta Di Blasi et al. · Nature Medicine · 2022 · 383 citations · Full text

Medicine, Hematology, Oncology +15